- Home
- Publications
- Publication Search
- Publication Details
Title
Selegiline: a molecule with innovative potential
Authors
Keywords
-
Journal
JOURNAL OF NEURAL TRANSMISSION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-28
DOI
10.1007/s00702-019-02082-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells
- (2019) Shikha Gaur et al. PROSTATE
- Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status
- (2019) Thomas Müller et al. Expert Opinion on Drug Metabolism & Toxicology
- A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease
- (2018) C. D. Binde et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats
- (2018) Csilla Terézia Nagy et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease
- (2018) Éva Szökő et al. JOURNAL OF NEURAL TRANSMISSION
- Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects
- (2018) Peter Riederer et al. JOURNAL OF NEURAL TRANSMISSION
- Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy
- (2018) Jean C. Shih JOURNAL OF NEURAL TRANSMISSION
- L‑Deprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration
- (2018) Ilhwan Ryu et al. ONCOLOGY REPORTS
- Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1
- (2017) Robert A. Hauser et al. Journal of Parkinsons Disease
- Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease
- (2016) Rodica Lighezan et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
- (2016) Mercedes Unzeta et al. Frontiers in Neuroscience
- Monoamine oxidases are novel sources of cardiovascular oxidative stress in experimental diabetes
- (2015) Adrian Sturza et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Safinamide for the treatment of Parkinson's disease
- (2014) Livia Dézsi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A Double-Blind, Placebo-Controlled Study of Selegiline Transdermal System in Depressed Adolescents
- (2014) Melissa P. DelBello et al. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
- Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain
- (2014) Joanna S Fowler et al. NEUROPSYCHOPHARMACOLOGY
- The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease
- (2013) Tamás Tábi et al. Expert Opinion on Drug Metabolism & Toxicology
- Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
- (2013) Jasmin Bartl et al. JOURNAL OF NEURAL TRANSMISSION
- Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials
- (2013) Lawrence W. Elmer PARKINSONISM & RELATED DISORDERS
- Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
- (2013) Kay Teo et al. Translational Neurodegeneration
- Selegiline
- (2012) Giovanni Fabbrini et al. CLINICAL NEUROPHARMACOLOGY
- Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
- (2012) Orly Weinreb et al. CURRENT DRUG TARGETS
- Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
- (2012) Makoto Naoi et al. CURRENT PHARMACEUTICAL DESIGN
- ‘‘70th Birthday Professor Riederer’’ Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (−)deprenyl: a way to a disease-modifying therapy?
- (2012) Wakako Maruyama et al. JOURNAL OF NEURAL TRANSMISSION
- The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model
- (2011) Gabor Bekesi et al. JOURNAL OF NEURAL TRANSMISSION
- Selegiline Transdermal System (STS) as an Aid for Smoking Cessation
- (2011) R. Kahn et al. NICOTINE & TOBACCO RESEARCH
- MAO-inhibitors in Parkinson's Disease
- (2011) Peter Riederer et al. Experimental Neurobiology
- Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy
- (2010) Joel D. Killen et al. ADDICTION
- Early Addition of Selegiline to L-Dopa Treatment is Beneficial for Patients With Parkinson Disease
- (2010) Yoshikuni Mizuno et al. CLINICAL NEUROPHARMACOLOGY
- R-Deprenyl: Pharmacological Spectrum of its Activity
- (2010) K. Magyar et al. NEUROCHEMICAL RESEARCH
- Selegiline use is associated with a slower progression in early Parkinson’s disease as evaluated by Hoehn and Yahr Stage transition times
- (2010) Y.J. Zhao et al. PARKINSONISM & RELATED DISORDERS
- Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
- (2010) Orly Weinreb et al. PROGRESS IN NEUROBIOLOGY
- (−)-Deprenyl Inhibits Thermal Injury-Induced Apoptotic Signaling and Hyperpermeability in Microvascular Endothelial Cells
- (2009) J Greg Whaley et al. Journal of Burn Care & Research
- Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
- (2009) C. W. Olanow NEUROLOGY
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- (−)-DEPRENYL INHIBITS VASCULAR HYPERPERMEABILITY AFTER HEMORRHAGIC SHOCK
- (2009) Binu Tharakan et al. SHOCK
- Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now